natgillin/translations-raw huggingface dataset:
is an optionally substituted benzyl group, wherein when a methylene group of the benzyl group comprises a substituent, it comprises 1 substituent selected from the group consisting of a methyl group, an ethyl group, an isopropyl group, a phenyl group, a 3-cyclopropylmethoxyphenyl group, and 4-fluorophenyl group; when a phenyl group of the benzyl group comprises a substituent, it comprises 1 to 2 substituents independently selected from the group consisting of a chlorine atom, a bromine atom, a fluorine atom, a methyl group, a trifluoromethyl group, an ethynyl group, an isobutoxy group, a 2-methylbutoxy group, an allyloxy group, a 2,2-difluoroethoxy group, a 2,2,2-trifluoroethoxy group, a cyclopentyloxy group, a cyclopropylmethoxy group, a tetrahydrofuran-3-yloxy group, and a tetrahydropyran-4-yloxy group. 
R' predstavlja atom vodika, a R* predstavlja skupinu benzila koji je po izboru supstituiran, gdje kada skupina metilena benzilne skupine ima supstituent, ona može imati 1 supstituent odabran od metilne skupine, etilne skupine, izopropilne skupine, fenilne skupine, 3-ciklopropilmetoksifenilne skupine i 4-fluorofenilne skupine; kada fenilna skupina skupine benzila ima supstituent, ona može imati 1 do 2 supstituenta odabrana od atoma klora, atoma broma, atoma fluora, skupine metila, skupine trifluorometila, skupine etinila, skupine izobutoksi, 2-metilbutoksi skupine, aliloksi = skupine, 2,2-difluoroetoksi skupine, 2,2,2-trifluoroetoksi = skupine, = ciklopentiloksi skupine, ciklopropilmetoksi skupine, tetrahidrofuran-3-iloksi skupine i tetrahidropiran-4-iloksi skupine.
The combination for use as claimed in any one of claims 1 to 6 for use in treating diseases and conditions caused by elevated intraocular pressure in a subject, wherein the diseases and conditions caused by elevated intraocular pressure in a human are selected from the group consisting of ocular hypertension, and primary open angle glaucoma. 
Kombinacija za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 6, za uporabu u liječenju bolesti i stanja uzrokovanih povišenim intraokularnim tlakom u subjekta, pri čemu su bolesti i stanja uzrokovana povišenim intraokularnim tlakom u čovjeka odabrana iz grupe koja se sastoji od okularne hipertenzije i primarnog glaukoma otvorenog kuta.
from about 0.0001 to 1% by weight of the seed before treatment). 
Tretirano sjeme, naznačeno time, što sadrži spoj iz Zahtjeva 1 u količini od oko 0.0001 do 1%, po težini sjemena prije tretmana.
A pharmaceutical composition comprising a compound of the formula (1) and an aqueous buffer, wherein: the composition has a pH of from about 5 to about 6, and 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3-6, gdje farmaceutska kompozicija ima pH od oko 4.
A valve gearbox as claimed in claim 12, wherein said valve monitoring sensor, said gate position sensor and said lid sensor, are reed switches that co-operate with respective permanent magnets, there being a valve monitoring sensor permanent magnet carried by said mounting flange, a gate position sensor permanent magnet carried by said arm, and a lid position sensor permanent magnet carried by said lid. 
Sklop za upravljanje ventilom s mehaničkim prijenosom prema Zahtjevu 6, gdje navedeni senzor (83) za nadzor nad ventilom, navedeni senzor (85) za položaj vrata ventila i navedeni senzor (91) poklopca Reedovi prekidači koji surađuju s respektivnim permanentnim magnetima, pri čemu je permanentni magnet senzora za nadzor nad ventilom nošen od strane navedene montažne prirubnice, permanentni magnet senzora položaja vrata ventila nošen od strane navedenog kraka i permanentni magnet senzora položaja poklopca nošen od strane navedenog poklopca.
The desired effect can be the prevention, alleviation or reduction of the severity of the psychosis or one or more symptoms thereof. 
Željeni učinak može biti prevencija, ublažavanje ili smanjivanje jačine psihoze ili jednog ili više njezinih simptoma.
A hybridoma that produces the monoclonal antibody of claim 1. 
Hibridoma koja proizvodi monoklonsko protutijelo iz patentnog zahtjeva 1.
is selected from the group consisting of hydrogen; alkyl; alkenyl; and alkynyl; 
je odabran od vodika; alkila; alkenila; i alkinila;
The device according to any one of claims 2 - 3, wherein at least one of the first and second engaging members comprises a tissue growth promoting structure (213) adapted to be in contact with the outer stomach wall to secure long term attachment of the stretching device to the stomach wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 2 do 3, naznačen time što najmanje jedan od prvog 1 drugog međudjelujućeg elementa ima strukturu koja potiče rast tkiva (213), prilagođenu da bude u kontaktu s vanjskom stijenkom želuca radi osiguravanja dugotrajne pričvršćenosti uređaja za rastezanje na stijenku želuca.
For complete deprotection, the residue (1.5 g, 0.79 mmo) is dissolved at 0° in TFA/H2O 95:5 (8.3 ml), and the mixture is stirred in the cold for 30 minutes. 
Za potpunu deprotekciju, ostatak (1.5 g, 0.79 mmo) se otopi na 0 *C u TFA/H20 95: 5 (8.3ml), te se smjesa miješa u hladnom tijekom 30 minuta.
The casing according to claim 1, wherein the fibers of the prepreg strip of the at least one reinforcement ply and/or the fibers of the prepreg plies are made of carbon fibers and/or glass fibers and/or aramide fibers and/or ceramic fibers. 
Omotač (1) prema bilo kojem od zahtjeva 1 do 7, naznačen time, da su vlakna (9) načinjena od ugljičnih vlakana i/ili staklenih vlakana i/ili aramidnih vlakana i/ili keramičkih vlakana.
The garment according to claim 1, wherein the first synthetic fibre material is texturized polyester. 
Odjevni predmet u skladu s patentnim zahtjevom 1, naznačen time, da prvi materijal od sintetičkih vlakana je teksturirani poliester.
To a solution of the intermediate from step D in anhydrous DMF (50 mL) was added cyanuric chloride (2.33 g, 13.2 mmol). 
U otopinu intermedijera iz koraka D u anhidridnom DMF (50 ml) je dodan cyanuric klorid (2.33 g, 13.2 mmol).
A packaging according to claim 1, wherein the first and/or second outer part comprises a surface relief comprising one of a hologram, a grating, and a picture. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što prvi i/ili drugi vanjski dio sadržava plošni reljef, takav kao što je hologram, raster ili slika.
the second antibody H chain consists of SEQ ID NO: 25; and 
(b9) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 25;
The CD19xCD3 bispecific single chain antibody construct for the use of claim 1, wherein said acute lymphoblastic leukemia (ALL) is B- lineage acute lymphoblastic leukemia, preferably B-precursor acute lymphoblastic leukemia. 
Konstrukt CD19xCD3 bispecifičnog jednolančanog protutijela za uporabu prema zahtjevu 1, naznačen time što navedena akutna limfoblastična leukemija (ALL) je akutna limfoblastična leukemija B-linije, poželjno B-prekursorska akutna limfoblastična leukemija.
In a particularly interesting aspect, the invention is directed to a method of treating incontinence comprising the use of the device of the invention, typically urinary incontinence or anal incontinence. 
U naročito zanimljivom aspektu je ovaj izum usmjeren na postupak za liječenje inkontinencije, kod kojeg postupka je obuhvaćena upotreba uređaja iz ovog izuma, tipično urinarne inkontinencije ili analne inkontinencije.
A formulation comprising an anti-EGFR ADC comprising an anti-EGFR antibody, or antigen-binding portion thereof, conjugated to monomethylauristatin F (MMAF), wherein said ADC 1-MMAF comprises a heavy chain variable region comprising complementarity domain regions (CDRs) comprising the amino acid sequences set forth in SEQ ID NOS: 15, 16, and 17, and comprises a light chain variable region comprising CDRs comprising the amino acid sequences set forth in SEQ ID NOS: 20, 21, and 22, sucrose, histidine, and polysorbate 80, wherein the formulation comprises an ADC mixture having an average DAR of about 3 or an ADC mixture having a DAR of about 2-4. 
Liofilizirana formulacija koja sadrži anti-EGFR ADC koji sadrži anti-EGFR protutijelo konjugirano na Monometilauristatin F (MMAF), pri čemu navedeni ADC sadrži varijabilnu regiju teškog lanca koja sadrži regije koje određuju komplementarnost (CDR- ove) koje sadrže amino aminokiselinske sekvence navedene u SEQ ID NOS: 15, 16, 1 17,1 sadrži varijabilnu regiju lakog lanca koja sadrži CDR-ove koje sadrže amino aminokiselinske sekvence navedene u SEQ ID NOS: 20, 21,1 saharozu, histidin, i polisorbat 80, pri čemu formulacija sadrži ADC smjesu koja ima prosječni DAR od oko 3 ili ADC smjesu koja ima DAR od oko
12: Reverse format binding ELISA of the pre-candidate pool antibodies to recombinant human Nogo-A (GST-Nogo-A 5+6). 
Slika 10: ELISA uz povralno vezanje protutijela iz fonda predkandidata s rekombinaninim ljudskim Nogo-A (GST-Nogo-A 5+6).
An apparatus according to claim 1, wherein the apparatus comprises an electronic cigarette configured to simulate a cigarette or a cigar without use of the cigarette or the cigar. 
E-cigareta (100) sukladno zahtjevu 1, naznačena time da je e-cigareta (100) izdužena i cilindrična da simulira cigaretu ili cigaru.
The method according to any one of claims 1 to 9, wherein the ammonia-lowering compound is selected from the group consisting of rifaximin and lactulose. 
Spoj za upotrebu prema zahtjevu 11 ili zahtjevu 12, naznačen time što je spoj koji snižava količinu amonijaka odabran iz skupine koja se sastoji od rifaksimina i laktuloze.
The data carrier as claimed in claim 13, wherein in the case of two metal layers, they are at a distance from one another of at least 100 micrometers. 
Nosač podataka prema jednom od zahtjeva 9 do 12, naznačen time da u slučaju dva metalna sloja, su oni razmaknuti jedan od drugog za najmanje 50 mikrometara, poželjno najmanje 100 mikrometara.
wherein the capsular polysaccharide is a Haemophilus influenzae type b (Hib) capsular polysaccharide, the improvement comprising preparing the capsular polysaccharide according to the method of claim 2 . 
- a) se antigen protiv Haemophilus influenzae tip b (Hib), koji sadrži kapsularni polisaharid (PRP), na industrijskoj razini, priprema u skladu s postupkom prema zahtjevu 1,
A therapeutic nanoparticle for use as a medicament, as claimed in any one of claims 1 to 13, wherein the nanoparticle includes about 1 to about 20 weight percent of the therapeutic agent, e.g. about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19 or about 20 weight percent of the therapeutic agent. 
Terapijska nanočestica u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačena time što nanočestice sadrže otprilike 1 do otprilike 20 težinskih postotaka terapijskog sredstva, primjerice otprilike 1, otprilike 2, otprilike 3, otprilike 4, otprilike 5, otprilike 6, otprilike 7, otprilike 8, otprilike 9, otprilike 10, otprilike 11, otprilike 12, otprilike 13, otprilike 14, otprilike 15, otprilike 16, otprilike 17, otprilike 18, otprilike 19 ili otprilike 20 težinskih postotaka terapijskog sredstva.
base (O2-base) is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide and mixture thereof. 
Baza (O2-baza) je iz skupine koja se sastoji od natrij-hidroksida, kalij-hidroksida, kalcij-hidroksida i njihovih mješavina.
A method according to claim 5, wherein the second medium comprises a basal medium for animal or human cells to which is added Epidermal Growth Factor; a FGF able to bind to FGFR2 or FGFR4, and HGF as mitogenic growth factors; gastrin; Nicotinamide; B27; N2; and N-Acetylcysteine. 
Postupak prema zahtjevu 4, pri čemu medij za diferencijaciju dalje obuhvaća deksametazon. Medij stanične kulture koji obuhvaća osnovni medij za životinjske ili humane stanice u koji se dodaje: EGF, FGF koji se može vezati za FGFR2 ili FGFR4, Nikotinamid, Wnt agonist izabran iz R-spondin 1, R-spondin 2, Rspondin 3 i R-spondin 4.
is C1-C8 alkyl, C3-C8 cycloalkyl, C5-C8 cycloalkenyl, (C1-C4 alkyl)-C3-C8 cycloalkyl or (C1-C4 alkyl)-C5-C8 cycloalkenyl, wherein the alkyl groups are each optionally substituted by one or more halogen atoms; or R1 and R6, together with the nitrogen and oxygen atoms to which they are attached, form a 5 to 10 membered heterocyclic group optionally substituted by one or more Z groups; 
je C1-C8 alkil, C3-C8 cikloalkil, C5-C8 cikloalkenil, (C1-C4 alkil)-C3-C8 cikloalkil ili (C1-C4 alkil)-C5-C8 cikloalkenil, gdje je svaka alkil-skupina opcijski supstituirana s jednim ili više atoma halogena; ili i R6, zajedno s atomima kisika i dušika na koje su priključeni, tvore 5 do 10-članu heterocikličku skupinu opcijski supstituiranu s jednom ili više Z-skupina;
A compound of any one of Claims 1 through 9 for use in inducing degradation of a c-kit, Bcr-Abl, FLT3, or EGFR, protein; inhibiting topoisomerase II; or modulating the activity of glucocorticoid receptors. 
HR P20140704 T1 Spoj bilo kojeg od zahtjeva 1 do 9 za uporabu u induciranju degradacije c-set, Bcr-Abl, FLT3, ili EGKR, proteina; inhibiranju topoizomeraze II; ili moduliranju aktivnosti glukokortikoid receptora.
The melter assembly of claim 12 in which the burners are arranged at a distance of about 250-750 mm from the side wall of said melting chamber. 
gdje se plamenici (21) nalaze na udaljenosti od 250 do 750 mm od bočne stijenke navedene komore za taljenje (3).
N-[4-(3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide, or a pharmaceutically-acceptable salt and/or solvate thereof. 
N-[4-(3-benzilpirolidin-1-il)-2-metilkinolin-6-il]benzamid, ili njihova farmaceutski prihvatljiva sol i/ili solvat.
The composition for use according to claim 1, or the use according to claim 2, or the compound for use according to claim 3, wherein the compound is administered at a concentration sufficient to inhibit cytokine IL-1a, B, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-a, LT, LIF, Oncostatin, or IFNc1a, B, Y. 
Pripravak za uporabu prema zahtjevu 1, ili uporaba prema zahtjevu 2, ili spoj za uporabu prema zahtjevu 3, naznačen time da se spoj primjenjuje u koncentraciji koja je dovoljna za inhibiciju citokina IL-1a, B, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, TNF-a, LT, LIF, Onkostatina, ili IFNc1a, B, Y.
Compound 69 was obtained as a hydrochloride salt from compound 68 by method B. 
Spoj 69 se dobiva kao hidrokloridna sol iz spoja 68 pomoću postupka B.
sealing the bottom and top impermeable sheets with respect to each other, 
- - brtvljenje gornje i donje nepropusne plohe jedne za drugu,
In other embodiments, formulations of the invention comprise an active ingredient selected from: 
PATENTNI ZAHTJEVI Oralna formulacija s trenutnim oslobađanjem, naznačena time, da sadrži djelatni sastojak odabran od:
Propulsion system according to claim 1, wherein said connecting arm comprises two sections set apart from each other, a single belt section passing through each said section. 
Pogonski sistem prema patentnom zahtjevu 1, gdje navedeni krak (200) za spajanje sadrži dva odjeljka (202) međusobno odvojena, pri čemu jedan odjeljak remena prolazi kroz svaki navedeni odjeljak (202).
Other possible surface-active agents include phospholipids, such as a lecithin; polyoxyethylene-polyoxypropylene copolymers, such as a Pluronic surfactant; polyoxyethylene esters of 12-hydroxystearic acid, such as a Solutol surfactant; ethoxylates of cholesterol, such as diacyl glycerol, dialkyl glycerol; bile salts, such as sodium cholate, sodium deoxycholate; sucrose esters, such as sucrose monolaurate, sucrose monooleate; polyvinyl pyrrolidone (PVP); or polyvinyl alcohol (PVA). 
Druga moguća površinski aktivna sredstva obuhvaćaju fosfolipide, kao što je lecitin; polioksietilen-polioksipropilen kopolimeri, kao što je Pluronic površinski aktivno sredstvo; poiioksietilen esteri 12-hidroksistearinske kiseline, kao što je Solutol površinski aktivno sredstvo; etoksilati kolesterola, kao što su diacil glicerol, dialkil glicerol; soli žučne kiseline, kao što su natrijkolat, natrij deoksikolat; esteri sa ha rože, kao što je saharoza monolaurat, saharoza monooleat; polivinil pirolidon (PVP); ili polivinil alkohol (PVA).
NNTP is compound (II) wherein R2 is a nitro group. 
Spoj iz patentnog zahtjeva 4, gdje R2 je nitro grupa, ili njegova sol.
interrupting data transmission over the output serial channel; 
- < prekidanje prijenosa podataka preko izlaznog serijskog kanala;
Owing to its composition, the fertilizer improves the fertility and the structure of soil and provides a simultaneous incorporation of all substances necessary to the soil and the plants in a single fertilizing step. 
Novo gnojivo djeluje na povećanje plodnosti i strukture tla, povećava prinos poljoprivrednih proizvoda i ne onečišćuje podzemne i nadzemne vode. Tehnički problem
The method of claim 1 or 2 wherein the compound of Formula I is a compound of Formula Ib: or a salt thereof and the compound of Formula II is represented by Formula IIb: or a salt thereof. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je spoj Formule I spoj Formule Ib: [image] Ili njihova sol te spoj Formule II je predstavljen Formulom IIb:
A compound, which is: or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 
Spoj s formulom: ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The pharmaceutical composition according to claim 5, which is a dosage form suitable for oral administration. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 20, naznačen time što je oblik doziranja pogodan za oralnu primjenu.
The controlled release composition according to claim 4 for administration twice daily. 
Sastav za kontrolirano otpuštanje u skladu s patentnim zahtjevom 1 za primjenu dvaput dnevno.
There is a first upper layer (5) whose external part is the one receiving solar radiation (1), since that external part is the surface of the receiver (2). 
Prijamnik (2) sunčevog zračenja (1) prema bilo kojem od zahtjeva 1 do 3 naznačen time što prijamnik (2) ima oblik geometrije šuplje polukugle.
A method for subscription and establishment of Internet services, wherein the method includes: 
Metoda pretplate i uspostave internetskih usluga koja uključuje:
Figure 1 is a sectional view of a portion of sheet according to the invention; 
prikazuje izgled presjeka dijela folije prema izumu; 1 slika 2
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Kombinacija sukladno patentnom zahtjevu 9, naznačena time, da je djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV 1 (b) B2 agonista.
The molecule for the use according to claim 17, wherein the immunoglobulin moiety is an immunoglobulin constant region or portion thereof. 
Molekula za primjenu u skladu sa patentnim zahtjevom 17, gdje imunoglobulinski segment je konstantni region imunoglobulina ili njegov dio.
Using this assay, the compounds of this invention were found to have an IC50 from less than 0.1 uM (see Table 1). 
Primjenom ovog testa, za spojeve ovog izuma je nađeno da imaju ICs, manje od 0.1 uM (vidi Tablicu 1).
the first fragment comprises a first proximal end within a first repeat portion; 
prvi fragment ima prvi proksimalni kraj;
In a further embodiment the polypeptide of the invention elicits a protective immune response in a mammalian host against strains of C.difficile. 
Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što polipeptid postiže zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
xanthan gum in a proportion comprising between 0.2% and 0.5%; 
- < ksantansku gumu, u udjelu koji se kreće između 0,2% 10,5%;
accordingly increase a duration of the predetermined time such that the active load absorbs from the candidate signal said predetermined amount of energy. 
odgovarajuće produljenje trajanja zadanog vremena (Tp) tako da aktivni teret (50) apsorbira iz kandidatnog signala (S.) navedenu zadanu količinu energije (E,).
Examples of protecting group, of protection and deprotection methods are given for example in Protective groups in Organic Synthesis Greene et al., 2nd Ed. (John Wiley & Sons, Inc., New York). 
Primjeri zaštitnih skupina, te postupaka postavljanja i uklanjanja zaštite dani su primjerice u Greene i dr.: "Protective Groups in Organic Synthesis", 2. izd (John Wiley & Sons, Inc., New York).
receiving, by a receiving section, a transmission wave of an external system and to generate a synchronization pulse in synchronization with a predetermined data frame of the transmission wave of the external system; 
prijem, dijelom za prijem, vala odaslanog iz vanjskog sustava i generiranja sinkronizacijskog impulsa sinkrono sa zadanim podatkovnim okvirom vala odaslanog iz vanjskog sustava;
The method of item 45, wherein the liver disease is fatty liver disease or hepatitis. 
Farmaceutski pripravak za uporabu prema zahtjevu 45, naznačen time da je bolest jetre, bolest masne jetre ili hepatitis.
Process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid 
Postupak za pripravu [1-hidroksi-2-(3-piridiniljetiliden| bisfosfonske kiseline
In another embodiment, a compound of Formula 7 is nitrated using a mixture of sulfuric acid, nitric acid and methylene chloride. 
= Postupak za dobivanje spoja 31, naznačen time da sadrži dovođenje u kontakt spoja 30 sa smjesom dušične kiseline i sumporne kiseline u prisutnosti diklorometana.
a polysaccharide, said polysaccharide having a polymer chain, said polymer chain being composed principally of fructose units linked together by B(2→1) glycosidic bonds at the anomeric C2, said polysaccharide being characterised by a degree of polymerisation, said degree of polymerisation being the number of monomer units in the polymer chain; 
polisaharid, pri čemu spomenuti polisaharid ima polimerni lanac, i spomenuti polimerni lanac se u suštini sastoji od fruktoznih jedinica koje su međusobno povezane s B(2→1) glikozidnim vezama na anomernom C2, pri čemu je spomenuti polisaharid naznačen sa stupnjem polimerizacije, i spomenuti stupanj polimerizacije je broj monomernih jedinica u spomenutom polimernom lancu;
wherein the included antibody, or antigen-binding fragment thereof, is detectably labeled. The method of claim 13 or claim 14, wherein the subject's folate receptor alpha (FRa) levels are indicative of the type of cancer afflicting the subject. 
Postupak u skladu s patentnim zahtjevom 13 ili patentnim zahtjevom 14, naznačen time što razine folatni receptor a (FRa) kod subjekta ukazuju na oblik raka od kojeg boluje subjekt.
H, C1-C5 alkyl, C3-C6 cycloalkyl. Compounds according to claim 1 or 2 selected from: 
Spojevi u skladu sa zahtjevom 1 ili 2, naznačeni time, da su izabrani iz slijedeće skupine: